Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting
Preclinical data demonstrates potential of piggyBac® DNA delivery system in developing gene therapies for the treatment of genetic liver disorders
P-BCMA-ALL01, Poseida’s first allogeneic CAR-T candidate targeting BCMA for relapsed/refractory (R/R) multiple myeloma, demonstrates potent activity in preclinical models
Preclinical data support anti-c-kit CAR-T as a preconditioning therapy for the transplantation of hematopoietic stem cells in patients with acute myeloid leukemia (AML)
SAN DIEGO, May 11, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting being held May 11-14, 2021.